
    
      This open-label, noncomparative, two-part phase 1B trial recruited patients with advanced,
      inoperable oesophageal cancer. The primary objectives were to assess the safety for donafenib
      tosylate tablets .The secondary objectives were to estimate tumor response, progression-free
      survival, duration of response, and disease control rate (response plus stable disease); to
      evaluate changes in quality of life(QoL); This study is 2-stages designing. The investigators
      plan to enroll 19 patients in the first stage study. The investigators will start the
      secondary stage study if the disease control rate >=8/19.
    
  